Press Releases
Hyperion Therapeutics to Present at the Citi 2011 Global Health Care Conference
South San Francico, California - February 25, 2011Hyperion Therapeutics, Inc. today announced that Donald Santel, Chief Executive Officer, will present at the Citi 2011 Global Health Care Conference on Tuesday, March 1 at 8:30 am Eastern Time. The conference will be held at the Hilton New York Hotel in New York City.
About Hyperion Therapeutics
Hyperion Therapeutics is a privately held pharmaceutical company focused on the development of therapies that address critical unmet needs in the areas of gastroenterology and hepatology. The Company is currently developing glycerol phenylbutyrate (HPN-100) for urea cycle disorders (UCD) and hepatic encephalopathy. Hyperion acquired development rights for glycerol phenylbutyrate from Ucyclyd Pharma, Inc. (a subsidiary of Medicis Pharmaceutical Corporation) in 2007 and has the right to acquire worldwide commercialization rights if the product is FDA-approved for UCD. Hyperion is headquartered in South San Francisco, CA. For additional information, visit www.hyperiontx.com.
Press contact:
Christine Nash
Hyperion Therapeutics, Inc.
650-745-7844